Biotechnology - Madison, Wisconsin, United States
Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of novel protein-based therapeutics as anti-cancer agents. The Company's products are based on the EVade™ Ribonuclease Technology which allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases. The EVade™ Ribonuclease technology is covered by patents acquired by the Company through an exclusive license with the University of Wisconsin. The Company's lead candidate, QBI-139, is in a Phase I human clinical trial at the University of Texas M. D. Anderson Cancer Center and the University of Wisconsin Comprehensive Cancer Center.
CloudFlare Hosting